BioSpace News Archive

Glycotope GmbH announces that it will present new data at the 2022 Society for Immunotherapy of Cancer Annual Meeting, being held in Boston, United States, between 8-12 November 2022.

Jiangsu Recbio Technology Co., Ltd. is pleased to announce that positive results were achieved for its primary vaccination Phase II study in the Philippines and heterologous booster vaccination Phase II study in United Arab Emirates in respect of its recombinant COVID-19 vaccine ReCOV.

BioArctic AB announced that the company has initiated a new project focused on enzyme replacement therapy for Gaucher’s disease in combination with the company’s Brain Transporter technology.

VectorY Therapeutics announces the appointment of Sander van Deventer, co-founder and formerly Chief Technology Officer, as Chief Executive Officer.

Cell growth and repair are stimulated by biomolecules known as cytokines and growth factors.

Neuronascent Inc., today announced its abstract entitled “Reduction of plasma p-Tau181 from a Phase 1a Randomized Trial of NNI-362 in a healthy aged population consistent with amelioration of tau hyperphosphorylation in human differentiated neuron cultures” has been accepted for a poster presentation at 15th Clinical Trials on Alzheimer’s Disease (CTAD 2022) to be held in San Francisco, Calif., on Nov. 29 through Dec. 2, 2022.

Evelo Biosciences, Inc. announced that Simba Gill, Ph.D., Chief Executive Officer of Evelo, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022, at 7:25 a.m. GMT.

Galecto, Inc. announced it will discuss topline data and additional analyses from its recently completed Phase 1b/2a GULLIVER-2 trial, including the observed statistically significant signs of liver protection, in a conference call and virtual webinar , Tuesday, November 8th at 8:00 a.m. ET.

MGFB, a subsidiary of FairWinds Bio (FWB), has entered into a patent license agreement with Mayo Clinic to advance experimental cancer vaccine therapeutics based on a novel platform developed over the past 20 years by Richard Vile, Ph.D., Mayo Clinic Professor of Immunology as well as several colleagues.

Swedish biotech company Salipro Biotech AB announced that it has entered into a research collaboration and license agreement with Sanofi on the discovery of therapeutic biologics against a challenging drug target.